Regenics Board of Directors 2016

 Tore Heldrup Rasmussen, MBA, Founder, Chairman of the Board. Mr. Rasmussen has been heading up several successful biotechnology companies prior to co-founding Regenics. Mr. Rasmussen brings many years of experience in strategy development and consumer products, as a Partner in MarkUp Consulting in Oslo and through tenures with Procter & Gamble and Orkla Foods (Norway). Mr. Rasmussen has an MBA degree from the University of Michigan.


Harald Nordal, MSc, MBA. Mr. Nordal serves on the Regenics Board of Directors and is the managing Director of Life Capitol AS, a Norwegian based holding company located in Hovdebygda, Norway, and a shareholder of Regenics. Mr. Nordal has a strong technical and managerial experience from the international operations of several Norwegian-based companies including Senior Project Manager of the oil and energy company StatoilHydro, Vice President of the technology and ship building company, Ulstein International, and Technical Director of Kværner Kleven. Prior to joining Life Capitol, Mr. Nordal held a position as Senior Vice President of the Norway division of Innovation Norway, promoting business development and cluster initiatives and as Project Director of the group’s global strategy development. He has served on the board of the seed money capital fund SIM and initiated other regional seed money initiatives. Mr. Nordal holds a MSc degree from the Norwegian University of Science and Technology, Trondheim, Norway and a MBA from CERAM, France.

Philippe Collas, PhD, Founder, Director and Scientific Adviser. Dr. Collas serves on the Regenics Board of Directors. He is Professor at the Institute of Medical Biochemistry of the University of Oslo, Norway, where he directs a laboratory of 20 people. Dr. Collas holds an engineering degree from France and a PhD from the University of Massachusetts. He has tremendous experience in research on nuclear reprogramming from academia (University of Massachusetts, Amherst College, University of Oslo) and industry in the United States. He was a co-founder of Nucleotech LLC (USA) and has served as Consultant for several Biotech Companies in Europe, United States and Australia. He has developed cell-free systems to investigate nuclear dynamics and gene function and has published over 100 scientific articles in the area of nuclear reprogramming. He was the first to show that somatic cells can be reprogrammed using cellular extracts. Dr. Collas is member of the Norwegian Academy of Science and Letters.



Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.